Purmorphamine
Purmorphamine is an agonist at Smoothened (Smo) receptors; it stimulates activity in the Hedgehog signaling pathway. Purmorphamine displays neuroprotective, pro-angiogenic, and anti-osteoporotic activities. In mesenchymal stem cells, this compound decreases proliferation, increases alkaline phosphatase activity, and accelerates osteogenesis. In animal models of stroke, purmorphamine restores neurological deficits, decreases neuronal apoptosis, and increases neovascularization. Purmorphamine also inhibits the induction of autophagy in hepatocellular carcinoma cells.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18955482
| Cas No. |
483367-10-8 |
|---|---|
| Purity |
≥98% |
| Formula |
C31H32N6O2 |
| Formula Wt. |
520.64 |
| IUPAC Name |
9-Cyclohexyl-N-[4-(4-morpholinyl)phenyl]-2-(1-naphthyloxy)-9H-purin-6-amine |
Wöltje M, Böbel M, Heiland M, et al. Purmorphamine and oxysterols accelerate and promote osteogenic differentiation of mesenchymal stem cells in vitro. In Vivo. 2015 Mar-Apr;29(2):247-54. PMID: 25792653.
Chechneva OV, Mayrhofer F, Daugherty DJ, et al. A Smoothened receptor agonist is neuroprotective and promotes regeneration after ischemic brain injury. Cell Death Dis. 2014 Oct 23;5:e1481. PMID: 25341035.
Wang Y, Han C, Lu L, et al. Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells. Hepatology. 2013 Sep;58(3):995-1010. PMID: 23504944.
